Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection

[1]  B. S. Sørensen,et al.  Optimal Reference Genes for Normalization of qRT-PCR Data from Archival Formalin-fixed, Paraffin-embedded Breast Tumors Controlling for Tumor Cell Content and Decay of mRNA , 2013, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[2]  Andrew H. Beck,et al.  Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype , 2013, Breast Cancer Research.

[3]  Simen Myhre,et al.  Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins , 2013, Molecular oncology.

[4]  H. Mouridsen,et al.  [Danish Breast Cancer Cooperative Group]. , 2012, Ugeskrift for laeger.

[5]  R. Greil,et al.  A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors , 2011, Clinical Cancer Research.

[6]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. Renoir,et al.  Cracking the estrogen receptor's posttranslational code in breast tumors. , 2011, Endocrine reviews.

[8]  Carsten Denkert,et al.  Quantitative Determination of Estrogen Receptor, Progesterone Receptor, and HER2 mRNA in Formalin-fixed Paraffin-embedded Tissue—A New Option for Predictive Biomarker Assessment in Breast Cancer , 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[9]  N. Udvarhelyi,et al.  Estrogen Receptor Negative and Progesterone Receptor Positive Breast Carcinomas—How Frequent are they? , 2011, Pathology & Oncology Research.

[10]  Hiltrud Brauch,et al.  Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. , 2010, Clinical chemistry.

[11]  A. Frigessi,et al.  In Silico Ascription of Gene Expression Differences to Tumor and Stromal Cells in a Model to Study Impact on Breast Cancer Outcome , 2010, PloS one.

[12]  L. Pusztai,et al.  Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. , 2010, The oncologist.

[13]  Rolf Jaggi,et al.  Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue , 2010, BMC Cancer.

[14]  M. J. van de Vijver,et al.  Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer , 2009, Clinical Cancer Research.

[15]  Uwe Rogel,et al.  RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. , 2009, Clinical chemistry.

[16]  A. Tutt,et al.  A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens. , 2009, The Journal of molecular diagnostics : JMD.

[17]  Krystyna Kiel,et al.  Breast cancer. Clinical practice guidelines in oncology. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  Edith A Perez,et al.  Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. B. Sørensen,et al.  Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Gelber,et al.  Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  F. B. Sørensen,et al.  Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. , 2008, Acta oncologica.

[22]  I. Christensen,et al.  Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications , 2008, Acta oncologica.

[23]  Ian O Ellis,et al.  Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Cronin,et al.  Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue , 2007, Breast Cancer Research and Treatment.

[26]  Lajos Pusztai,et al.  Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. , 2007, The Lancet. Oncology.

[27]  S. Hilsenbeck,et al.  The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Paik,et al.  Technology Insight: application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer , 2005, Nature Clinical Practice Oncology.

[29]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[30]  Mårten Fernö,et al.  Comparison of Immunohistochemical and Biochemical Assay of Steroid Receptors in Primary Breast Cancer Clinical Associations and Reasons for Discrepancies , 2003, Acta oncologica.

[31]  P. Bendahl,et al.  Estrogen and Progesterone Receptor Assay in Paraffin-Embedded Breast Cancer , 2003, Acta oncologica.

[32]  H. Storm,et al.  Validity and Representativity in the Danish Breast Cancer Cooperative Group , 2003, Acta oncologica.

[33]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Bentzen,et al.  Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation. , 1988, European journal of cancer & clinical oncology.

[35]  H. J. G. GUNDERSEN,et al.  Some new, simple and efficient stereological methods and their use in pathological research and diagnosis , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[36]  B. S. Sørensen,et al.  Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  Debjani Dutta,et al.  Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. , 2004, The American journal of pathology.